Holen Sie sich die Stockscreener-App
54.59
0.61%
0.4186
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE) - Insider Monkey
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Stock Price, Quote & Chart | XENON PHARMACEUTICALS INC (NASDAQ:XENE) - ChartMill
5 Best Performing Canadian Stocks So Far in 2026 - Insider Monkey
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown - Sahm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - AOL.com
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus - AD HOC NEWS
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
XENE: Azetukalner’s strong efficacy and novel mechanism set the stage for a major epilepsy market launch - TradingView
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares - Stock Titan
XENE Maintained by JP Morgan -- Price Target Raised to $80.00 - GuruFocus
Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan - Moomoo
Xenon anticipates AZK NDA in Q3 2026 amid launch timing at end of 2027 or early 2028 - MSN
Equities Analysts Set Expectations for XENE Q2 Earnings - MarketBeat
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway - Yahoo Finance
Insiders At Xenon Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - Moomoo
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative? - Yahoo Finance
Nan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $63 to $80.65 - Moomoo
Xenon Pharmaceuticals Q1 earnings call highlights - MSN
Xenon Pharmaceuticals Q1 Earnings Call Highlights - sharewise.com
Xenon Pharmaceuticals Maps Path After Standout XTOL-2 - TipRanks
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus - Yahoo Finance
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
Needham Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $78 - Moomoo
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $74 to $80.65 - Moomoo
Xenon Pharmaceuticals (XENE) Achieves Milestones Ahead of FDA Su - GuruFocus
Xenon Pharmaceuticals 1Q Rev $0.00 >XENE - Moomoo
William Blair Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $80.65 - Moomoo
Earnings call transcript: Xenon Pharmaceuticals Q1 2026 results show mixed signals - Investing.com Nigeria
Xenon Pharmaceuticals Q1 Loss Widens - Moomoo
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18 - marketscreener.com
Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission - ChartMill
Xenon Pharmaceuticals (XENE) deepens Q1 loss but amasses $1.34B cash war chest - Stock Titan
Xenon Pharmaceuticals: Q1 Earnings Snapshot - kare11.com
A seizure drug filing is next, but Xenon has 5 more Phase 3 studies running - Stock Titan
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & Headlines - Yahoo Finance
Xenon Reports Q1 2026 Financial Results and Provides Business Update - The Manila Times
Big cash raise and strong Phase 3 results headline Xenon (XENE) Q1 2026 - Stock Titan
Xenon Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Xenon Pharmaceuticals faces earnings test as launch nears - Investing.com UK
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):